Cargando…

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations

BACKGROUND: Blood eosinophil counts and history of exacerbations have been proposed as predictors of patients with chronic obstructive pulmonary disease (COPD) who may benefit from triple therapy (inhaled corticosteroid, long-acting β(2)-agonist and long-acting muscarinic antagonist). METHODS: In a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vogelmeier, Claus F., Kostikas, Konstantinos, Fang, Juanzhi, Tian, Hengfeng, Jones, Bethan, Morgan, Christopher Ll, Fogel, Robert, Gutzwiller, Florian S., Cao, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686508/ https://www.ncbi.nlm.nih.gov/pubmed/31391053 http://dx.doi.org/10.1186/s12931-019-1130-y

Ejemplares similares

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population
por: Vestbo, Jørgen, et al.
Publicado: (2019)

Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database
por: Kostikas, Konstantinos, et al.
Publicado: (2020)

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study
por: Vogelmeier, Claus F, et al.
Publicado: (2018)

Exacerbations of COPD
por: Viniol, Christian, et al.
Publicado: (2018)

In ‘real world’ patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations
por: Worth, Heinrich, et al.
Publicado: (2023)

Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients
por: Kostikas, Konstantinos, et al.
Publicado: (2020)

Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD
por: Kostikas, Konstantinos, et al.
Publicado: (2018)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017)

Pulmonary biomarkers in COPD exacerbations: a systematic review
por: Koutsokera, Angela, et al.
Publicado: (2013)

High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients – a retrospective analysis
por: Greulich, Timm, et al.
Publicado: (2020)

The association between eosinophilic exacerbation and eosinophilic levels in stable COPD
por: Kang, Hye Seon, et al.
Publicado: (2021)

Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial
por: Beeh, Kai M, et al.
Publicado: (2013)

Patient-Reported Outcomes (PROs) in COPD Clinical Trials: Trends and Gaps
por: Afroz, Nuzhat, et al.
Publicado: (2020)

Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study
por: Kostikas, Konstantinos, et al.
Publicado: (2020)

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
por: Buhl, Roland, et al.
Publicado: (2018)

Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®)
por: Vogelmeier, Claus F., et al.
Publicado: (2015)

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study
por: Greulich, Timm, et al.
Publicado: (2018)

Variability of blood eosinophil count and prognosis of COPD exacerbations
por: Martínez-Gestoso, Sandra, et al.
Publicado: (2021)

Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study
por: Wedzicha, Jadwiga A., et al.
Publicado: (2019)

COPD Exacerbation History and Impact on Future Exacerbations – 8-Year Retrospective Observational Database Cohort Study from Germany
por: Vogelmeier, Claus F, et al.
Publicado: (2021)

Stability in eosinophil categorisation during subsequent severe exacerbations of COPD
por: Citgez, Emanuel, et al.
Publicado: (2021)

COPD Assessment Test Changes from Baseline Correlate with COPD Exacerbations: A Longitudinal Analysis of the DACCORD Observational Study
por: Kardos, Peter, et al.
Publicado: (2020)

Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients
por: Ställberg, Björn, et al.
Publicado: (2018)

IgE is associated with exacerbations and lung function decline in COPD
por: Lommatzsch, Marek, et al.
Publicado: (2022)

The Role of Digital Tools in the Timely Diagnosis and Prevention of Acute Exacerbations of COPD: A Comprehensive Review of the Literature
por: Konstantinidis, Athanasios, et al.
Publicado: (2022)

Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort
por: Greulich, Timm, et al.
Publicado: (2018)

COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils
por: Eltboli, Osama, et al.
Publicado: (2014)

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
por: Siddiqui, Salman H, et al.
Publicado: (2018)

Relationship Between Blood Eosinophils and Systemic Corticosteroid Therapy in COPD Exacerbation
por: Gong, Yaya, et al.
Publicado: (2022)

Patients' perspectives on COPD: findings from a social media listening study
por: Cook, Nigel S., et al.
Publicado: (2019)

Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study
por: Mackay, Alexander J., et al.
Publicado: (2020)

Eosinophilic and non-eosinophilic COPD patients with chronic respiratory failure: neutrophil-to-lymphocyte ratio as an exacerbation marker
por: Acartürk Tunçay, Eylem, et al.
Publicado: (2017)

Cardiovascular predictors of mortality and exacerbations in patients with COPD
por: Alter, Peter, et al.
Publicado: (2022)

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
por: Shukla, Soham, et al.
Publicado: (2021)

Transcriptional analysis identifies potential biomarkers and molecular regulators in pneumonia and COPD exacerbation
por: Bertrams, Wilhelm, et al.
Publicado: (2020)

Renaming COPD exacerbations: the UK respiratory nursing perspective
por: Mwasuku, Christine, et al.
Publicado: (2021)

Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations
por: Bartziokas, Konstantinos, et al.
Publicado: (2023)

COPD management costs according to the frequency of COPD exacerbations in UK primary care
por: Punekar, Yogesh Suresh, et al.
Publicado: (2014)

Neutrophil-to-lymphocyte ratio, blood eosinophils and COPD exacerbations: a cohort study
por: Ellingsen, Jens, et al.
Publicado: (2021)

Systemic steroids in COPD-the beauty and the beast
por: Vogelmeier, Claus F
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nebs8rc8p4n56uqkcvsnsn0or3